

***Revised 90898, Editorial***

***Title: Approaches and Challenges in Cancer Immunotherapy Pathways***

Dear Sirs,

Thank you very much for this thorough review, which helped me clarify my manuscript and enrich it. I responded to all comments and suggestions raised by the reviewers with appropriate amendments. Moreover, I cite one additional study. The sections that were revised or added in response to the review appear highlighted. Detailed, point-by-point responses to the review comments follow.

Thank you for considering our manuscript for publication in *World Journal of Clinical Oncology*.

Sincerely yours,

Dr. Maria Kapritsou

## **Response to reviewers' comments**

### **REVIEWER 1**

**Comment 1:** “Tumor mutation burden (TMB) plays a vital role within efficient tumor immunity targets, inhibiting their growth and hence therapeutic regression.” This sentence has a grammatical error.

**Response:** English editing was made by native speaker (highlighted text).

**Comment 2:** “Experimental neogenic vaccines focused primarily on pinpointing TMJ could expand field discoveries, significantly improving patient outcome prospects, and ultimately, born-out research progression.” What is the meaning of TMJ in this sentence. Should be TMB?

**Response:** The necessary change was made from TMJ to Tumor mutation burden (highlighted text).

**Comment 3:** Could the author more specifically summaries the approaches and challenges in targeting TMB.

**Response:** The 4th and 5th paragraphs summarize the approaches and challenges to targeting TMB (highlighted text).

### **REVIEWER 2**

#### **ABSTRACT**

**Comment:** The immunotherapy of tumor is a hot topic at present, and the conclusion stated by the author is fairer. Although this therapy is not a panacea, it still has great research prospects. There is no problem in the content of the paper, and various problems in clinical use are summarized. From a clinical point of view, the paper is worth publishing

**Response:** Thank you for your comments

### **REVIEWER 3**

**Comment:** The author briefly described three approaches of cancer immunotherapy, with less emphasis on the challenges faced by cancer immunotherapy. There are no particularly meaningful viewpoints or valuable concepts worth learning from. This is an editorial article. Perhaps due to word count limitations, the author did not elaborate well on the content related to the article title.

**Response:** English editing was made by native speaker (highlighted text). The 6th paragraph summarizes the approaches and challenges in immunotherapy. (highlighted text).